that EU angle is very interesting especially if they can enter in a low cost way. Then again you would not expect crazy growrh but it would be good to sell there. The main focus should be US tbh as resources should be heavily focused on the FDA approval. It is the largest market and if they get the approval they should jack up the prices. Current pricing is not helping the company to sustain revenue growth.
that EU angle is very interesting especially if they can enter...
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
